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Abstract Since most of our knowledge on pharmacological 
properties of brain 5-HT4 receptors have been discussed for 
mouse colliculi neurons, we cloned the corresponding receptor 
using the RT-PCR approach. As expected, the homology with 
the already cloned rat 5-HT4L receptor was high, revealing only 
16 differences at the amino-acid level. One of the differences, 
proline 75 in mouse, alanine 75 in the already published rat 
sequences was not confirmed. Therefore this proline is part of 
the consensus equence present in all 5-HT receptor transmem- 
brane domain II (LVMP). Comparing the aff'mities of 11 
agonists and five antagonists for the cloned mouse receptor (5- 
HT4L ) expressed in LLCPK1 and the corresponding receptor in 
mouse colliculi shows an excellent correlation. The transfected 
mouse 5-HT4L receptor stimulated cAMP production. When 
expressed at high density, it exhibited intrinsic activity. In 
contrast to the previously described distribution, we found that 
mRNA encoding for both the short (5-HT4s) and the long form 
(5-HT4L) of 5-HT4 receptors are expressed in all mouse and rat 
brain areas. 
K~ v words: Mouse colliculi; 5-HT4 receptor; Cloning; 
D~ ~tribution; Splice variant 
1. Introduction 
~-HT4 receptors are expressed in a wide variety of tissues of 
ve:tebrates including rodent, porcine and human brain, guin- 
ea. pig ileum and colon, rat oesophagus, frog and human adre- 
n(,-cortical cells, human urinary bladder, human and porcine 
hetrt [1 3]. In the alimentary tract, 5-HT4 agonists such as 
m, toclopramide and cisapride are therapeutically used as pro- 
kiaetic drugs. In brain, a role for 5-HT4 receptors in cognition 
is likely [1]. 5-HT4 receptors were first described in mouse 
ce liculi neurons, as a 5-HT receptor positively coupled to 
act enylyl cyclase (AC) and having a unique pharmacology, 
clearly different from that of 5-HT1, 5-HT2 and 5-HTa recep- 
toJs [4]. Nowadays, 5-HT4 pharmacology includes many 
highly specific antagonists such as GR 113808 and SB 
204070 which are also excellent radioligands [5-8]. Most of 
the pharmacological and transductional studies on 5-HT4 
have been performed in mouse colliculi neurons, guinea-pig 
ile am, and rat oesophagus. Although the pharmacology of 5- 
H ~'4 receptors in these preparations i very similar, some un- 
ex ~lained differences exist. For example, benzamides, are full 
a~z mists in colliculi neurons and partial agonists or antago- 
nists in most other prepartions (guinea-pig ileum and distal 
co on, rat hippocampus) [2]. A difference in coupling efficiency 
is anlikely to explain these differences because in distal guin- 
ea pig colon, a preparation in which the potency for 5-HT is 
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the highest, the benzamides are still partial agonists [9]. In 
addition, a recent report describes differences between phar- 
macology of the 5-HT4 receptor in guinea pig colon and those 
present in rat oesophagus when novel 5-HT4 compounds were 
used [10]. In order to understand these differences and in 
particular whether they correspond to species differences, to 
tissue differences or to coupling differences intrinsic to the 
receptor molecule, cloning of these receptors is necessary. So 
far, only 5-HT4 receptors from rat brain have been cloned, a 
tissue from which we have very few functional studies. In this 
report we have cloned and studied the pharmacology of the 5- 
HT4L receptor from mouse colliculi, a preparation in which 
most of our knowledge on 5-HT4 receptor pharmacology and 
transduction processes has been established [3,11]. 
2. Materials and methods 
2.1. Isolation and sequencing of the mouse 5-HT4 cDNA by RT-PCR 
Total RNA was isolated from colliculi neurons in primary culture 
prepared from 14-15-day-old Swiss mouse embryos [12]. Poly(A) + 
RNA was extracted with Dynabeads Oligo(dT)25 (Dynal) and reverse 
transcribed using Superscript II Rnase H Reverse Transcriptase (Life 
Technologies) and random nonamers. RT-PCR were performed with 
oligonucleotides (ON), ON1-EcoRI (International Patent WO94l 
14957, Sequence 3, position 48-71) 5'-CGGAATTCTAATGGACA- 
GACTTGATGCTAATG-3', in the beginning of the 5' coding se- 
quence flanked with an EcoRI site, and ON2-XbaI (Patent, Sequence 
3, position 1322-1340) 5'-GCTCTAGATTGCCTCATGCACTT- 
GAA3', in the 3' non-coding sequence, flanked with an XbaI site. 
PCR was performed with the Vent DNA Polymerase (N.E. Biolabs): 
94°Cl3 min followed by 30 cycles of denaturation (94°Cl30 s), anneal- 
ing (54°Cl30 s) and elongation (72°C/1 min 45 s). We used two suc- 
cessive PCR to have sufficient amplification. To confirm the sequence 
of the 5' part of the receptor around the ATG codon, we performed a 
PCR reaction using the following primers: ON3 (Patent, Sequence 1, 
position 21~41) 5'-GGTTGGAAGGAGGAGGATGCT-Y, in the 5' 
non-coding sequence, and ON4 (Patent, Sequence 1, position 648 
670) 5'-GAGGAGAAACGGGATGTAGAAGG-3', in the middle 
of the receptor sequence. The PCR conditions with Taq DNA Poly- 
merase (Eurobio) were: 94°Cll min followed by 35 cycles of denatura- 
tion (94°Cl30 s), annealing (56°Cl30 s) and elongation (72°Cll rain). 
Fragments (701 bp) were subcloned using the TA Cloning method 
(Invitrogen). 
2.2. Tissue localisation studies 
Brain areas were dissected from adult OFA rats, from new born (1 
day) and adult Swiss mice. cDNA was obtained as described above 
from poly(A) + RNA. Primers designed to carry out PCR amplifica- 
tion were: ON1 for the two forms of the receptor and ON7 (Patent, 
Sequence 1, position 1227-1248) 5'- AGGGACTCTGGGT- 
CATTGTGTA-Y for the 5-HT4s or ON2 for the 5-HT4L, ON8 
(J00691, position 2252-2271) 5'-GACTCCGGAGACGGGGTCAC- 
3' and ON9 (J00691, position 2482-2501) 5'-CGCATCCTCTT- 
CCTCCCTGG-Y for [~-actin. The PCR conditions were those de- 
scribed above for the Taq DNA Polymerase, with an annealing at 
55°C. The expected sizes of the PCR fragments were 1150 bp for 5- 
HT4s, 1293 for 5-HTaL and 450 bp for 13-actin. PCR products were 
run on 1% agarose/ethidium bromide gels and photographed. A pos- 
itive control was performed with rat 5-HT4s and L cDNA (a generous 
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1 ta ATG GAC AAA CTT GAT GCT AAT GTG AGT TCC AAC GAG GGT TTC AGG TCC GTG GAGIAAG 59 
1 M D ~, L D A N  V S S N E G F ~ S V E ,K 19 
m • X 
60 GTC GTG CTG CTC ACG TTC CTT  
20 V V L L T F 
GCA GTG GTT ATC CTG ATG GCC ATC TTG GGC AAC CTG CTG 119 
A ~ V I L M A I L G N L L 39 
120 GTG ATG GTG GCT GTG TGC AGG GAC AGG CAG CTC AGG KAAA ATA KAAA ACC AACITAT  TTC A T T 4 0  V M V A V C R D R Q L R I T N F I 59179 
X$ 
180 GTG TCT CTC GCC TTT GCT GAC 
60 V S L A F A D 
240 GAG CTG GTC CAA GAC ATC TGG 
80 E L V Q D I W 
CTG CTG GTT TCG GTG CTG G~G ATG CCC TTT GGT GCC ~TT] 239 
v v v A 
300 GAT GTC CTA CTC ACC ACA GCA TCG ATC TTT CAC CTG TGC TGT ATT  TCC CTG[GAC AGG TAT 359 
i00 D V L L T T A S I F H L C C I S L ID  m Y 119 
360 TAC Gcc  ATe TGC TGC tag  COT TTG GTT TaT AGe aac  mG ATG aCC COT CTA CGClaTC GCa 419 
120 Y A I C C Q P L V Y R N K M T P L R I I  A 139 
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TTA ATG TTG GGA GGC TGC TGG 
L M L G G C W 
GGC TGGIAAC AAC ATC GGC ATA 
G W I N N I G I 
NAAC TCC ACG TGG TGT GTC TTC S T ~ C V F 
• V 
GCC TTC TAC ATC CCG TTT CTC 
A F Y I P F L 
AAG GAG CAT 
K E IH  
CCC CAG CCA 
P Q 
AcTT  T 
GCC CAG CAG ATA 
i Q Q I 
GTC CTT  CCC ATG TTT ATA TCT TTT CTC CCC ATA ATG CAA 479 
V ~ P M F I S F L P I M Q 159 
m 
GTT GAT GTG ATA GAG AAA AGG AAA TTC AGC CAC AAC TCT 539 
V D V I E K R K F ~ H N S 179 
ATG GTC AAC AAG CCC TAT GCT ATC ACC TGC TCT GTG GTG 599 
M V N K P Y A I T C S V V 199 
CTC ATG GTG CTG GCC TAT TACICGA ATC TAT  GTC ACT GCT 659 
m M V L A Y Y lm I Y V I T A  219 
CAG ATG TTA CAA CGG GCA GGA GCC ACC TCT GAA AGC AGG 719 
Q M L Q R A G A T S E S R 239 
GCT GAC CAG CAC 
A D Q H 
AGC ACA CAT CGC ATG AGG ACA GAG ACC AAG GCA GCC AAG 779 
S T H R M R T E T K A A K 259 
• VI 
GTC ATC ATG GGC TGC TTC TGT TTC TGC TGG GCC CCC TTC TTT  GTC ACC AAT 839 
V I M G C F C F C W A P F F V T N 279 
ATT  GTG GAC CCTI 
m I I V D 
CTT  GGC TAT ATC 
L G Y I 
TTC ATA GAC TAC ACT GTC CCC GAG CAG GTG TGG ACT GCT TTC CTC TGG 899 
F I D Y T V P E ~ V W T A F L W 299 
VI I  
~T TCG GGG TTG ~C OCT TTT CTC TAT GCC TTC TTGI~T ~C TOT TTC 959 
N S G L N P Z B Y A F L I N K S F 319 
AGA CGT GCC TTC CTC ATC ATC 
R R A F L I I 
CTG GGC CAG ACT GTC CCC TGT 
L G Q T V P C 
GAT GCA GTG GAA TGT GGT GGC 
D ~ V E C G G 
TTG GTG GCT GCT CAG CCA GTG 
L V A A Q P V 
GGC TTG AAA CGA AGC CAG TCC 
L K R S Q S 
CTC TGC TGT GAT GAT GAG CGC TAC AAA AGA CCC CCC ATT  1019 
L C C D D E R Y K R P P I 339 
TCA ACC ACA ACC ATT  AAT GGA TCC ACC CAT GTA CTA AGG 1079 
S T T T I N G S T H V L R 359 
CAG TGG GAG AGT CGG TGT CAC CTC ACA GCA ACT TCT CCT 1139 
Q W E S R C H L T A T S P 379 
ATA CTT  AGG CCC CTG GAC AAT GAC CTA GAA GAC AGC TGT 1199 
I ~ R P ~ D N D L E D S C 399 
TAA gctgctact tg tgtgtatgtggctggccctggcactc tc t tc tccaag  1271 
407 
gct t tccaagagcagaggcaa  1292 
Fig. I. Nucleotide sequence of the mouse 5-HT4L cDNA. The receptor was sequenced on both strands from ON1 (position l) to the end of 
ON2 (position 1292). The seven putative transmembrane domains are boxed and numbered (I to VII). Changes in mouse amino acids versus rat 
amino acids are shaded and rat amino acids are indicated under, e, sites of potential N-linked glycosylation. 0 ,  site of potential 
palmitoylation. A, consensus sites for phosphorylation by protein kinase C. (-- - -  --), consensus site of phosphorylation by calmoduline kinase 
2. ~r, terminal stop codon. 
gift from Dr. Christophe Gerald). Southern blotting was done after 
transfer of the DNA to charged nylon membranes (Qiabond, Qiagen). 
The hybridization probe was an EcoRI-BamHI fragment containing 
the 5' non-coding region and the common region of the two 5-HT4 
forms to the BamHI site (Patent, Sequence 1, position 1157) labeled 
using the Prime-ltII Random Primer Labeling Kit (Stratagene). 
2.3. TransJection of LLCPK1 cells 
5-HT4 cDNAs were subcloned into pRK5, a CMV based expres- 
sion vector [13] and introduced into LLCPK1 ceils (a gift from Dr. 
Falk Fahrenholz, Germany) by electroporation. Briefly, cells were 
trypsinized, centrifuged, resuspended in EP lx  buffer (50 mM 
K2HPO4/20 mM CHaCO2K]20 mM KOH/26.7 mM MgSOJpH 7.4) 
with 10-200 ng of receptor cDNA. After 15 min at room temperature, 
300 gl of cell suspension (106 cells) were transferred to a 0.4 cm 
electroporation cuvette (Biorad) and pulsed using a Gene pulser ap- 
paratus (setting: 950 gF, 260 V). Cells were diluted in DMEM (106 
cells/ml) containing 10% foetal bovine serum dialysed (FBSd) and 
plated on 10 cm Falcon petri dishes or into 12-well clusters. 
2.4. Cyclic AMP assays 
Six hours later, cells were incubated overnight with 2 I.tCi 3H-la- 
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be]ed adenine to label the ATP pool and cAMP accumulation was 
measured as described [14]. 
2.5 Membrane preparations and radioligand binding assay 
Membranes were prepared from transiently transfected LLCPK1 
cells plated on 10 cm dishes and grown in DMEM with 10% FBSd 
fol 6 h and 20 h in DMEM without FBSd. The cells were washed 
tx~ ~ce in PBS, scraped and harvested in the same buffer and centri- 
fu~ed at 4°C, 900×g for 4 min. The cell pellet was resuspended in
bt~ffer containing 10 mM HEPES (pH 7.4), 5 mM EGTA, 1 mM 
El ~TA and 0.32 M sucrose and homogenized with a glass-Teflon 
hc,'aaogenizer at 4°C (10 shakes). The homogenate was centrifuged 
at 20,000×g for 20 min, the membrane pellet was resuspended in
5[~ mM HEPES (pH 7.4) (5 mg of protein in 1 ml of solution) and 
st, red at -25°C until used for radioligand binding studies with 3H- 
la!,eled GR 113808 (specific activity: 83 Ci/mmol) as previously de- 
sc~ ibed [8]. 
2. '. Data analysis 
2ompetition and saturation experiments were analysed by non-lin- 
ea ' regression using the LIGAND software [15]. 
3. Resu l ts  
3. '. Cloning and primary amino acid sequence of  the mouse  
5-HT4L receptor 
Recently, Gerald et al. [16] reported that the transcripts of 
tb~ 5-HT4L form were expressed throughout  the brain, 
wlereas those of the short form (5-HTas) were limited to 
the mouse striatum. We performed RT-PCR experiments 
w th poly(A) + RNA prepared from mouse embryo colliculi 
n, urons using the primers (see Section 2) designed to clone 
tl~e long form of the 5-HT4 receptor (5-HTaL). The resulting 
fr tgments (1293 bp) were double digested by EcoRI and XbaI 
aJd  ligated into pRK5-neo. Double-stranded DNA was se- 
____> 
F~g. 2. A: Scatchard analysis of saturation experiments of 3H-la- 
bLled GR 113808 binding to the mouse 5-HT4L receptors. Mem- 
branes (1~20 ~tg of protein/sample) harvested from transiently 
tr~=nsfected LLCPK1 cells, electroporated with 10, 50, or 200 ng of 
m )use 5-HT4L receptor cDNA/106 cells, were incubated with 8 dif- 
feent concentrations of SH-labeled GR 113808 (0.01 1.8 nM) for 
3~ min at 20°C. B: Correlation between the affinities of 16 5-HT4 
d] ags (11 agonists and 5 antagonists) for 3H-labeled GR 113808 to 
the" cloned mouse 5-HT4L receptors versus the affinities of the same 
d;ugs for 3H-labeled GR 113808 binding sites in mouse colliculi 
ntarons. Binding data corresponds to competition of :~H-labeled 
G t~, 113808 binding to membranes of LLCPK1 cells transiently ex- 
p] essing mouse 5-HT4L receptors (750 fmol/mg protein). ICs0 values 
required to displace 50% of 3H-labeled GR 113808 binding were de- 
temined experimentally and converted to Kd values according to 
th: Cheng-Prussoff equation [29]: Kd =ICso/(I+S/Kds) where S is 
th. • 3H-labeled GR 113808 concentration (0.2 nM) and Kds the 
e¢ uilibrium constant of 3H-labeled GR 113808. On the Y axis are 
relgorted the pKd values of 16 5-HT4 drugs (see below) for cloned 
m )use 5-HTaL receptors and on the X axis, the pKd values of the 
s~ "ne drugs for 5-HT4 binding sites in colliculi neurons taken from 
[I !]. For each drug the following values correspond to the pKd for 
cl reed mouse 5-HT4L receptors and to the pKd for 5-HT.I binding 
sies in colliculi neurons, respectively: (1) 5-HT: 7.25+0.12; 
7 +_11; (2) 5-MeOT: 6.64+-0.23; 6.28+-0.17; (3) 5-CT: 5+-0.12; 
5 l l+0.2; (4) RN 76186: 8.54_+0.18; 8.86__.0.05; (5) SC53116: 
8 i3+0.2;  8.1+0.08; (6) Cisapride: 7.49-+0.09; 7.29+-0.24; (7) 
R ~'nzapride: 6.88+0.11; 7.01 +-0.12; (8)(S)Zacopride: 6.72+0.15; 
6 ~5_+0.15; (9) Metoclopramide: 6.05-+0.13; 5.4+-0.18; (10) BIMU 
8 7.39+-0.23; 7.6+0.18; ( l l )  BIMU l: 7.54+-0.16; 7.27+0.18; 
(12) GR 125487: 10.65_+0.43; 10.42+-0.10; (13) GR 113808: 
9 59+-0.32; 9.5+-0.20; (14)ICS 205930: 7.06+-0.35; 6.8_+0.30; (15) 
S[)Z 205557: 8.11-+0.25; 8.2+-0.22; (16) DAU 6285: 7.26+-0.28; 
7 ~7 + 0.15. 
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quenced. The sequence was performed on three different 
clones from three independent PCR reactions. The sequence 
of the 5' part of the receptor, around the ATG codon was 
controlled using another pCR fragment prepared with differ- 
ent oligonucleotides ( ee Section 2). Sequence analysis re- 
vealed one long open reading frame (406 amino acids) (Fig. 
1). As expected, the homology with rat 5-HT4 cDNA was 
high. However, 52 differences in the nucleotide sequence 
were present giving 16 differences in the amino-acid sequence. 
Compared to rat 5-HT4L receptor, note that the N-glycosyl- 
ated site and most of consensus amino acids and sequences of 
biogenic amine receptors were conserved such as: the aspar- 
rates in t ransmembrane domains (TMD)- I I  (D66) and TMD-  
III (D100) engaged in the coupling to G protein and the 
ligand binding respectively, the cysteines of extracellular l oops  
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el and e2 likely to be engaged in a disulfide bridge, the DRY 
sequence at the N-terminus of the second intracellular loop i2 
so important for activation of these receptors [17], the prolines 
in TMD-V, TMD-VI  and TMD-VI I  and a cysteine (C328) 
which is a potential palmitoylation site [18,19]. Mouse 5- 
HT4L receptor carries only two potential protein kinase C 
(PKC) phosphorylation sites (over three present in rat recep- 
tor). Amino acid sequence comparison of the C-terminus tail 
of mouse and rat 5-HT4L receptors revealed a high level of 
identities, both are rich in serine and threonine residues (14 in 
mouse compared to 16 in rat). As previously demonstrated for 
the 132-adrenergic receptor some of these residues are potential 
phosphorylation sites for G receptor protein kinase (GRK)s 
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Fig. 3. A: Stimulation of cAMP production by increasing concen- 
trations of 5-HT in LLCPK1 cells transiently expressing either the 
mouse 5-HT4L or the rat 5-HT4L or the rat 5-HT4s receptors. Cells 
were electroporated with 200 ng of each receptor cDNA/106 cells. 
In the absence of agonist he percentage conversions of [3H]ATP to 
[all]cAMP in LLCPK1 without transfection or transfected either 
with rat 5-HT4s or rat 5-HT4L or mouse 5-HT4L receptor cDNA 
were 0.11 +0.05%, 0.12+0.03%, 0.14+0.06% and 0.55+0.17%, re- 
spectively. In the presence of 100 gM 5-HT the conversions were 
0.25+0.08%, 0.710+0.16%, 0.820+0.13%, and 1.23+0.11%, respec- 
tively. The results are expressed as the percentage stimulation of ba- 
sal activity. B: Stimulation of cAMP formation by increasing con- 
centrations of 5-HT in the absence or in the presence of 30, 100 or 
300 nM of the highly selective 5-HT4 antagonist: GR 113808, in 
LLCPK1 cells expressing mouse 5-HT4L (200 ng of receptor cDNA/ 
106 cells). In the absence of 5-HT, the basal percentage conversions 
of [3H]ATP to [3H]cAMP were 0.57+0.15%, 0.52+0.6%; 
0.60+ 0.4% and 0.51 + 0.7%, respectively, in the absence and in the 
presence of 30, 100 or 300 nM of GR 113808 100 gM. In the pres- 
ence of 100 gM 5-HT, the maximal conversion obtained was 
1.1 + 0.18%. Results are expressed as percentage of stimulation rela- 
tive to the maximal stimulatory effect of 5-HT. In (A) and (B) each 
curve represents the mean from three separate experiments per- 
formed in duplicate. 
[20]. In the transmembrane domains, five differences within 
the amino-acid sequences of rat and mouse receptors were 
noted, including at position 75 in TMD-I I ,  an alanine in rat 
which was occupied by a proline in the mouse sequence. In 
addition, a proline (P242) was present in the third intracellular 
loop (i3) of mouse 5-HT4L receptor which was absent in rat 5- 
HT4L receptor (T242). 
3.2. Pharmacological characterization of mouse 5-HT4L 
receptor 
The cDNA encoding the mouse 5-HT4L receptor was tran- 
siently transfected in LLCPK1 cells. No detectable binding 
was found in mocked transfected cells using all-labeled GR 
113808, as specific 5-HT4 ligand (data not shown). The ex- 
pression of receptors in LLCPK1 cell membranes increased 
with the amount of DNA transfected (Fig. 2A). Only a single 
category of binding sites was observed (Ks = 0.22 + 0.07 nM). 
In order to compare the pharmacological properties of the 
cloned mouse 5-HT4L receptor with those of the 5-HTa recep- 
tor expressed in native colliculi neurons [11] we measured the 
affinities of 11 agonists and five antagonists using displace- 
ment experiments. All the displacement curves were mono- 
phasic, giving a Hill coefficient not different from 1. A re- 
markable correlation (r=0.978) was found between the 
affinities of agonists and antagonists for 5-HTa receptor in 
colliculi neurons and for the cloned mouse 5-HTaL receptor 
transfected in LLCPK1 (Fig. 2B). We also verified that the 
mouse 5-HT4L receptor transiently expressed in LLCPK1 was 
positively coupled to AC. The EC~0 of the 5-HT dose-con- 
centration curves obtained in transfected cells with the mouse 
--.> 
Fig. 4. Central distribution of 5-HTas and 5-HT4L transcripts. RT-PCR analysis performed with 100 ng of poly(A +) RNA from various struc- 
tures of new born mouse brain (A,B), adult mouse brain (C) and adult rat brain (D). The PCR amplified products were resolved by 1% agar- 
ose/ethidium bromide gel electrophoresis, photographed and analysed by Southern blotting (see Section 2). Southern blot of new born mouse 
brain PCR results exposed 90 min to X-ray films (B). Specific primers based on the known rat eDNA sequences 5-HT4s, 5-HT4L or actin (see 
Section 2) were used on poly(A +) RNA treated with (+S, +L, A) or without reverse transeriptase (-S, -L). A positive control was done by 
PCR reaction performed with rat cDNA clones encoding 5-HTas and 5-HT4L receptors. The marker fragments indicated on the right and the 
left of the photograph show that the size of the PCR products (about 1300 bp) correspond to the total cDNA encoding 5-HT4s and 5-HT4L re- 
ceptors. 
S. Claeysen et al./FEBS Letters 398 (1996) 19 25 23 
and rat 5-HT4 receptors cDNA (200 ng) were significantly 
different, 8+3 nM (n=6), 35+12 nM (n=4) and 24+_7 nM 
(n = 4) for mouse 5-HT4L, rat 5-HT4L and rat 5-HT4s, respec- 
tively (Fig. 3A). Another clear difference was an increase in 
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basal AC level in cells transfected with mouse 5-HT4L recep- 
tors compared to that transfected with rat 5-HT4 receptors 
(Fig. 3A). This increase in basal AC activity corresponded 
to an intrinsic activity of the mouse 5-HT4 receptor, i.e., a 
coupling in the absence of agonist, and not to an agonist 
stimulated form of the receptor since this basal activity was 
not decreased by the highly potent antagonist GR 113808 at a 
concentration of 300 nM (see legend to Fig. 3B) which com- 
petitively inhibits the 5-HT dose-response curve (Ki=0.8 
nM_+0.3) (Fig. 3B). This intrinsic activity of mouse 5-HT4 
receptor not seen with rat 5-HT4 receptors was certainly due 
to a much higher expression of mouse 5-HT4 receptor in 
LLCPK1 cells. Indeed, for the same amount of transfected 
cDNA (200 ng of cDNA/106 cells) we obtained 8 pmol and 
0.1 pmol of mouse and rat 5-HT4L receptor expressed per mg 
of protein. 
3.3. Distribution o f  5-HT4s and 5-HT4L receptors in new born 
and adult mouse brain as well as in adult rat brain 
Gerald et al. [16] described that 5-HT4L receptors are widely 
distributed in rat brain whereas 5-HT4s has a very specific and 
unique expression in rat striatum. In order to evaluate a pos- 
sible differential splicing during development, we decided to 
verify if this also occurs in new born mouse brain. Using pairs 
of primers specific for each isoform (see Section 2), we ampli- 
fied cDNA derived from mRNA coding for the two splice 
variants from different brain areas (Fig. 4A). The identifica- 
tion of two fragments (1150 and 1293 bp) corresponding to 
sequences of 5-HT4s and 5-HT4L, respectively, was based on 
two criteria: (1) a positive control was done by PCR reaction 
performed with rat 5-HT4s and 5-HT4L cDNA (a generous 
gift from Dr. Christophe Gerald) (Fig. 4A), (2) Southern blot- 
ting and hybridization with a 3zP-labeled probe common to 
both splice variants (5' region ~ position 1157 probe) under 
high stringency specifically labeled the same fragments (Fig. 
4B). The hybridization signals were not due to the contami- 
nating genomic DNA, since 5-HT4s and 5-HT4L primers 
failed to yield any PCR fragments in the minus reverse tran- 
scriptase controls (Fig. 4A, B). Since the presence of 5-HT4s 
mRNA in all new born mouse brain areas was unexpected 
[16], we studied the distribution of the 5-HT4 receptor iso- 
forms in both mouse and rat adult brains for comparison. 
Finally, both 5-HT4 receptor isoforms mRNA were present 
in all mouse and rat brain areas (Fig. 4C,D). 
4. Discussion 
We have isolated cDNA encoding the 5-HT4L receptor by 
RT-PCR on poly(A) + RNA from mouse colliculi using spe- 
cific primers designed from the sequence of the rat 5-HT4L 
cDNA. As expected, the sequence homology with the rat 5- 
HT4L isoform was very high. Only 16 residues were different 
between the rat and mouse sequences of 5-HT4L receptor. 
Three of these differences deserve specific comments. 
(1) The residue at position 75, in TMD II, is an alanine in 
rat and a proline in mouse 5-HT4 receptors. The importance 
of the TMD II, in binding of ligands to receptors for biogenic 
amines, is well documented [18,19]. The proline 75 found in 
mouse 5-HT4 receptors is part of a consensus sequence 
(LVMP) found in TMD II of all 5-HT receptors [21], except 
in rat 5-HT4 in which the corresponding sequence is LVNA 
[16]. This striking amino acid sequence conservation i all 5- 
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HT receptors except in rat 5-HT4 receptor was very surpris- 
ing. Therefore, we decided to sequence this region in both rat 
brain 5-HT4L and 5-HT4s cDNA obtained by RT-PCR with 
poly(A) + RNA prepared from total brain. Our sequence anal- 
ysis revealed that indeed in rat 5-HT4 receptors, the sequence 
is also LVMP. 
(2) The presence of a proline in the middle of the third 
intracellular loop (i3) (P242) of the mouse receptor, which is 
the position equivalent to a threonine in the rat receptor, may 
have a crucial role in coupling to G proteins or to other 
putative functions of the third loop, such as cellular targeting. 
(3) The suppression of a putative PKC phosphorylation site 
in the mouse 5-HT4L receptor compared to the rat 5-HT4L 
receptor since position 400 in the C-terminus is occupied by 
a glycine and a serine, respectively. We have no information 
about a possible desensitization f 5-HT4 receptors via PKC. 
In contrast, we do know that 5-HT4 receptors in mouse col- 
liculi neurons and rat oesophagus are rapidly desensitized via 
homologous desensitization [22,23]. The homologous desensi- 
tization is certainly related to the phosphorylation of the nu- 
merous serine and threonine residues present in C-terminus 
(14 in mouse, 16 in rat 5-HT4L), but also in the second and 
third intracellular loops [20,24]. The absence of cAMP-PKA- 
mediated esensitization f mouse 5-HT4 receptors [22,23] is 
certainly related to the absence of consensus equence for 
phosphorylation by PKA in the mouse 5-HT4 receptor clone 
described here. 
The pharmacological profile of the mouse 5-HT4L receptor, 
cloned from colliculi neurons is identical to that of native 
mouse colliculi neurons when the affinity constants of both 
agonists and antagonists are considered. The mouse 5-HT4L 
receptor clone was much more efficacious than the rat recep- 
tor clone in terms of receptor synthesis and expression. The 
reason for this difference in expression is unknown. It could 
be related to the non-coding sequences present in the 5' and 3' 
regions which are very short in the mouse 5-HT4L cDNA 
clone compared to the rat 5-HT4L and 5-HT4s cDNA clones. 
The analysis of the untranslated regions reveals many initiator 
ATG followed by termination codons. These regions might 
affect translation efficiency and/or mRNA stability. These ob- 
servations are in agreement with earlier reported ata which 
demonstrates that removing the 5' untranslated region con- 
taining several ATG codons separated by short reading 
frames and termination codons, results in a 10-fold increase 
in translation of the ~2AR mRNA [25]. In our case, absence 
of the 5' untranslated region lead to an overexpression of
mouse 5-HT4L receptor which gives a constitutive coupling 
to Gs protein and constitutive activation of AC. Such a con- 
stitutive coupling has been described in three situations. (1) In 
some receptor families like the metabotropic glutamate recep- 
tor family, some spliced variants are spontaneously coupled to 
G proteins [26]. (2) In some receptors specific mutations 
(found in pathologies or experimentally done) give a consti- 
tutive activity [27]. (3) Overexpression of some receptors like 
the I]2-adrenergic receptors both in vitro and in vivo lead to a 
constitutive activation of Gs [28]. 
Finally, one of the most suprising findings of the present 
report was the fact that the two splice variants of 5-HT4 
receptors (5-HT4L and s) were expressed in all areas of adult 
mouse and rat brain studied as well as in new born mouse 
brain. This is in contrast o the report of Gerald et al. [16] 
who, using a similar PCR method, described a unique expres- 
S. Claeysen et al./FEBS Letters 398 (1996) 19~5 
si,)n of 5-HT4s in rat striatum. The reason for this discrepancy 
is unknown and deserves further investigation. 
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